RxDoctor Payments Data

Hui Kim, MD

Nephrology · Metairie, LANPI 1639191661

Payments from drug & device makers

$2,112in general payments, 2019–2025

Across 84 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$300
  • Lilly USA, LLC$238
  • AstraZeneca$193
  • Mallinckrodt Hospital Products Inc.$143
  • Boehringer Ingelheim$142
  • Calliditas Therapeutics US Inc.$103
  • plus $993 from 17 others

What the payments were for

  • Food & beverage$1,97894%
  • Education$1346%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,112 in reported general payments places this provider in the 45th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$147,017
Medicare patients
298
Services billed
934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin287$230,827
FilspariSparsentan11$128,164
FarxigaDapagliflozin Propanediol138$99,261
VelphoroSucroferric Oxyhydroxide24$86,602
KerendiaFinerenone67$50,852
VeltassaPatiromer Calcium Sorbitex19$21,062
LokelmaSodium Zirconium Cyclosilicate25$20,338
JanuviaSitagliptin Phosphate27$19,881
TradjentaLinagliptin17$16,904
MounjaroTirzepatide11$13,397
DapagliflozinDapagliflozin Propanediol15$8,302
Sevelamer Carbonate63$8,073
Calcium Acetate75$6,427
ProsolParenteral Amino Acid 20% No.150$5,224
Valsartan184$3,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$142$247,730304 claims
Travere Therapeutics, Inc.Filspari$68$128,16411 claims
AstraZenecaFarxiga, Lokelma$193$119,600163 claims
Fresenius USA Marketing, Inc.Velphoro$87$86,60224 claims
BayerKerendia$99$50,85267 claims
Lilly USA, LLCMounjaro$238$13,39711 claims
ANI Pharmaceuticals, Inc.Valsartan$21$3,179184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 206 nephrology providers in Louisiana.

Other nephrology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →